Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships

Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced today*. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.

Six new Fellowships funded by Celgene as part of a commitment to translational medicine at Oxford

Six new Oxford-Celgene Fellowships will support postdoctoral researchers and clinicians across six departments within the Medical Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development. The new Fellowships represent an additional investment of £3M into the University.

Medical Sciences welcomes Dr Thakurta as Visiting Professor

Medical Sciences Division is delighted to welcome Dr Anjan Thakurta to Oxford, having now taken up his position of Visiting Professor of Cancer, Biology and Translational Science within the Radcliffe Department of Medicine.

'Family trees' of Acute Myeloid Leukaemia treated with enasidenib mapped for the first time

The study led by MRC WIMM researchers as part of an international team aims to understand what happens when patients stop responding to treatment.